Huntington's disease: effect of memantine on FDG-PET brain metabolism?

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Huntington's disease : effect of memantine on FDG-PET brain metabolism? / Hjermind, Lena Elisabeth; Law, Ian; Jønch, Aia; Stokholm, Jette; Nielsen, Jørgen Erik.

I: The Journal of Neuropsychiatry and Clinical Neurosciences, Bind 23, Nr. 2, 2011, s. 206-10.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hjermind, LE, Law, I, Jønch, A, Stokholm, J & Nielsen, JE 2011, 'Huntington's disease: effect of memantine on FDG-PET brain metabolism?', The Journal of Neuropsychiatry and Clinical Neurosciences, bind 23, nr. 2, s. 206-10. https://doi.org/10.1176/appi.neuropsych.23.2.206

APA

Hjermind, L. E., Law, I., Jønch, A., Stokholm, J., & Nielsen, J. E. (2011). Huntington's disease: effect of memantine on FDG-PET brain metabolism? The Journal of Neuropsychiatry and Clinical Neurosciences, 23(2), 206-10. https://doi.org/10.1176/appi.neuropsych.23.2.206

Vancouver

Hjermind LE, Law I, Jønch A, Stokholm J, Nielsen JE. Huntington's disease: effect of memantine on FDG-PET brain metabolism? The Journal of Neuropsychiatry and Clinical Neurosciences. 2011;23(2):206-10. https://doi.org/10.1176/appi.neuropsych.23.2.206

Author

Hjermind, Lena Elisabeth ; Law, Ian ; Jønch, Aia ; Stokholm, Jette ; Nielsen, Jørgen Erik. / Huntington's disease : effect of memantine on FDG-PET brain metabolism?. I: The Journal of Neuropsychiatry and Clinical Neurosciences. 2011 ; Bind 23, Nr. 2. s. 206-10.

Bibtex

@article{557f83d37b61433d8e3262c44b7628a3,
title = "Huntington's disease: effect of memantine on FDG-PET brain metabolism?",
abstract = "In this open-label pilot study, the authors evaluated the effect of memantine on the distribution of brain glucose metabolism in four Huntington's disease (HD) patients as determined by serial 18-fluoro-deoxyglucose [F(18)]FDG-PET scans over a period of 3-4 months (90-129 days, with one patient choosing to continue treatment over the 18-month follow-up period). The treatment regimen was well tolerated. No significant differences on neuropsychological parameters before and after treatment were detected; but the patient who continued treatment did not deteriorate at 18 months' reevaluation, whereas the three patients who had stopped treatment after 3 to 4 months had minor progression in all cognitive domains on re-evaluation 12 months after the end of treatment.",
keywords = "Adult, Brain, Disease Progression, Excitatory Amino Acid Antagonists, Glucose, Humans, Huntington Disease, Memantine, Middle Aged, Neuropsychological Tests, Pilot Projects, Receptors, N-Methyl-D-Aspartate",
author = "Hjermind, {Lena Elisabeth} and Ian Law and Aia J{\o}nch and Jette Stokholm and Nielsen, {J{\o}rgen Erik}",
year = "2011",
doi = "10.1176/appi.neuropsych.23.2.206",
language = "English",
volume = "23",
pages = "206--10",
journal = "Journal of Neuropsychiatry and Clinical Neurosciences",
issn = "0895-0172",
publisher = "American Psychiatric Publishing, Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Huntington's disease

T2 - effect of memantine on FDG-PET brain metabolism?

AU - Hjermind, Lena Elisabeth

AU - Law, Ian

AU - Jønch, Aia

AU - Stokholm, Jette

AU - Nielsen, Jørgen Erik

PY - 2011

Y1 - 2011

N2 - In this open-label pilot study, the authors evaluated the effect of memantine on the distribution of brain glucose metabolism in four Huntington's disease (HD) patients as determined by serial 18-fluoro-deoxyglucose [F(18)]FDG-PET scans over a period of 3-4 months (90-129 days, with one patient choosing to continue treatment over the 18-month follow-up period). The treatment regimen was well tolerated. No significant differences on neuropsychological parameters before and after treatment were detected; but the patient who continued treatment did not deteriorate at 18 months' reevaluation, whereas the three patients who had stopped treatment after 3 to 4 months had minor progression in all cognitive domains on re-evaluation 12 months after the end of treatment.

AB - In this open-label pilot study, the authors evaluated the effect of memantine on the distribution of brain glucose metabolism in four Huntington's disease (HD) patients as determined by serial 18-fluoro-deoxyglucose [F(18)]FDG-PET scans over a period of 3-4 months (90-129 days, with one patient choosing to continue treatment over the 18-month follow-up period). The treatment regimen was well tolerated. No significant differences on neuropsychological parameters before and after treatment were detected; but the patient who continued treatment did not deteriorate at 18 months' reevaluation, whereas the three patients who had stopped treatment after 3 to 4 months had minor progression in all cognitive domains on re-evaluation 12 months after the end of treatment.

KW - Adult

KW - Brain

KW - Disease Progression

KW - Excitatory Amino Acid Antagonists

KW - Glucose

KW - Humans

KW - Huntington Disease

KW - Memantine

KW - Middle Aged

KW - Neuropsychological Tests

KW - Pilot Projects

KW - Receptors, N-Methyl-D-Aspartate

U2 - 10.1176/appi.neuropsych.23.2.206

DO - 10.1176/appi.neuropsych.23.2.206

M3 - Journal article

C2 - 21677252

VL - 23

SP - 206

EP - 210

JO - Journal of Neuropsychiatry and Clinical Neurosciences

JF - Journal of Neuropsychiatry and Clinical Neurosciences

SN - 0895-0172

IS - 2

ER -

ID: 38425999